Topics

Companies Related to "Basal Tumours in Bladder Cancer, Response to chemoTherapy" [Most Relevant Company Matches] RSS

19:30 EDT 23rd October 2019 | BioPortfolio

Here are the most relevant search results for "Basal Tumours in Bladder Cancer, Response to chemoTherapy" found in our extensive corporate database of over 50,000 company records.

Showing "Basal Tumours Bladder Cancer Response chemoTherapy" Companies 1–25 of 3,000+

Extremely Relevant

Bladder Cancer Advocacy Network

The Bladder Cancer Advocacy Network (BCAN - pronounced beacon) is the first national advocacy organization dedicated to improving public awareness of bladder cancer, advancing bladder cancer research and providing information and support to people affected by bladder cancer. Founded in May 2005, BCAN is a cooperative effort among bladder cancer survivors, their loved ones and the medical community...


Relevant

KIYATEC, Inc.

KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated...

Sonrgy, Inc.

Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focus...


TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www...

Bristol-Myers Squibb and TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www....

DiaTech Oncology

DiaTech Oncology is a privately held clinical pathology laboratory that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s...

Onconome, Inc.

Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...

ProCertus BioPharm, Inc.

ProCertus BioPharm is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.ProCertus has established proof of concept in animal models for its product candidates, DermX, ProDermaCel™, and OralX, proprietary pharmaceuticals designed to reduce or eliminate the side effects associated with cancer thera...

Modra Pharmaceuticals B.V.

Modra Pharmaceuticals aims to re-define taxane chemotherapy by developing therapies that are less toxic, more effective and can be taken at home in tablet form. The Company’s goal is to radically improve the therapeutic outcomes and everyday lives of the hundreds of thousands of cancer patients undergoing taxane chemotherapy worldwide. Modra’s lead program is advancing into Phase 2 clin...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

YM BioSciences

YM BioSciences is a product development company. Our focus is to advance cancer products along the regulatory and clinical pathways towards commercial approval. YMB does not conduct basic research; rather, our product portfolio is established through a process of careful, rational selection of therapeutics produced in research institutions around the globe. We have one of the broadest oncology po...

Gendal Limited

Gendel Limited is developing a safe novel medical device technologu for the treatment of solod cancer tumours in the absence of any drug

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Valeritas, Inc.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) technology. The first use of the h-Patch(TM) technology will be the V-Go(TM) Disposab...

Valeritas LLC

Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. The Valeritas medical technologies portfolio is headlined by the h-Patch(TM) technology. The V-Go Disposable Insulin Delivery Device, designed for the...

Emmerex

Emmerex is an early stage bio-pharmaceutical company. It aims to bring to market an anti-cancer therapy. The Emmerex therapy arose as a result of several years' biological research. It has already been proven to be safe in patients. The Emmerex therapy utilises the patients' own innate ability to fight cancer. It cuts off nutrient source of the cancer and attacks the tumours directly. The Emmerex ...

BSD Medical

BSD Medical Corporation (AMEX: BSM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD Medical is also making major progress in the application of its technology for other therapies. Microwave and RF hyperthermia therapy has been shown to substantially improve local con...

Cancer Therapeutics, Inc.TM

Founded in 1991, Cancer Therapeutics, Inc.TM (CTI) is a biotherapy company that is a leader in activated cell technology for cancer therapy. CTI's laboratory offers access to technologies grouped under the modality of Biotherapy. Biotherapy is based on treatments that enhance the patient's own immune system to attack the invading cancer. Research has shown cancer to be a highly individualized dise...

Medifocus Inc.

Medifocus owns a patented microwave focusing technology platform the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of hea...

Medifocus, Inc.

Medifocus owns a patented microwave focusing technology platform the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of hea...

Vesiflo, Inc.

Vesiflo, Inc. is dedicated to reinventing bladder drainage. Due to their acute need, our initial focus is on improving the lives of women with atonic bladder. We also plan to add related products through internal development and acquisition. Learn more at www.vesiflo.com.

Rainier Therapeutics, Inc.

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic and early stage bladder cancer, an area of high unmet need. The company’s antibody, vofatamab (B-701) is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of...

Biomoda, Inc.

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development ...

TARIS Biomedical

TARIS Biomedical Inc., a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatments h...

Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled in...


More From BioPortfolio on "Basal Tumours in Bladder Cancer, Response to chemoTherapy"

Quick Search

Corporate Database Quicklinks